Sprint Bioscience has entered into a collaboration agreement with the Lundberg Laboratory for Diabetes Research at Gothenburg University, Sweden, where Sprint Bioscience will develop drug candidates against a new target protein that is central to the development of type 2 diabetes (T2D).
Diabetes is a research area that fits well within the Sprint Bioscience portfolio. There are many links between diabetes and cancer. It’s long been known that T2D increases cancer risk, but also that the lengthy use of certain diabetes medications may reduce the risk of cancer. Sprint Bioscience has good experience both of the target class in this collaboration, and also of the metabolic processes in the body that we want to influence.
Sprint Bioscience has already identified chemical series in the project and a chemistry program is in place. The molecules will be evaluated in disease models developed at the Lundberg Laboratory for Diabetes Research.